Bronchiectasis clinical trials at UC Davis
1 research study open to eligible people
Showing trials for
Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”
open to eligible people ages 12-85
The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.
Sacramento, California and other locations